Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Pfizer Japan to Discontinue Amoxapine after Carcinogen Issue
Pfizer Japan said on February 19 that it will discontinue the sale of its antidepressant Amoxan (amoxapine), which has been under shipment suspensions, as the company has no prospects for resuming production following the detection of carcinogen impurities. The company…
To read the full story
Related Article
- Pfizer Japan Begins Amoxapine Recall, Ceases Shipments over Carcinogen Risks
February 27, 2023
- Pfizer Assesses Cancer Risk from Amoxan as “Acceptable” at “1 in 200,000 People”
October 26, 2022
- Pfizer Japan to Stop Amoxapine Shipments, Start Recall in February after Carcinogen Detection
September 7, 2022
- Pfizer Japan to Curb Shipments and Recall Amoxapine over Carcinogen Risks
September 1, 2022
BUSINESS
- MSD Files Oral PCSK9 Inhibitor Enlicitide in Japan
September 15, 2026
- Takeda’s Zasocitinib Gets FDA Priority Review in Plaque Psoriasis
September 15, 2026
- CMIC Names CFO Yoshida as New President
September 15, 2026
- Eisai Teams with Osaka Prefecture on Dementia, MCI Awareness
September 15, 2026
- Enhertu PFS Hits 14.3 Months in PIII for 1st-Line NSCLC
September 15, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…